Exenatide once weekly (EQW ) + Dapagliflozin (DAPA) + EQW plus DAPA + Dapagliflozin plus Glucophage (MET ER) + Phentermine /Topiramate (PHEN/ TPM) ER
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Polycystic Ovary Syndrome
Conditions
Polycystic Ovary Syndrome, Obesity
Trial Timeline
Mar 22, 2016 → Oct 9, 2020
NCT ID
NCT02635386About Exenatide once weekly (EQW ) + Dapagliflozin (DAPA) + EQW plus DAPA + Dapagliflozin plus Glucophage (MET ER) + Phentermine /Topiramate (PHEN/ TPM) ER
Exenatide once weekly (EQW ) + Dapagliflozin (DAPA) + EQW plus DAPA + Dapagliflozin plus Glucophage (MET ER) + Phentermine /Topiramate (PHEN/ TPM) ER is a phase 3 stage product being developed by AstraZeneca for Polycystic Ovary Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT02635386. Target conditions include Polycystic Ovary Syndrome, Obesity.
What happened to similar drugs?
3 of 13 similar drugs in Polycystic Ovary Syndrome were approved
Approved (3) Terminated (4) Active (6)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02635386 | Phase 3 | Completed |
Competing Products
20 competing products in Polycystic Ovary Syndrome